Estrella Immunopharma, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 08 Sep 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 21 Aug 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 13 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Quarterly report filed late (NT 10-Q)
The company filed Form NT 10-Q with the SEC on 18 May 2026, notifying investors that its quarterly report would be late. Late filings can point to accounting or business problems, though the reason is sometimes routine.
More details →Estrella Immunopharma, Inc. — Overview & Financial Snapshot
Estrella Immunopharma, Inc. (NasdaqCM: ESLA) is a Healthcare company, ranked #6,404 of 6,774 companies globally and #3,669 of 4,000 in United States on PositoAI, with a Positivity Score of -18,867. Its market capitalisation is ₹298.41 Cr ($31.61M), P/E ratio is -2.9 and P/B ratio is -4.25. It currently has 3 active red flags (PosiRed) and 1 yellow flag (PosiYellow, 2/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →